Faricimab as Treatment for Sarcoid Uveitis With Refractory Cystoid Macular Edema.

IF 0.8 Q4 OPHTHALMOLOGY
Ting-Han Lin, Hung-Yi Lin, Yu-Hsun Chuang, Po-Chen Tseng
{"title":"Faricimab as Treatment for Sarcoid Uveitis With Refractory Cystoid Macular Edema.","authors":"Ting-Han Lin, Hung-Yi Lin, Yu-Hsun Chuang, Po-Chen Tseng","doi":"10.1177/24741264251358628","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> To describe the first use of the bispecific monoclonal antibody faricimab for sarcoid uveitis with refractory cystoid macular edema (CME). <b>Methods:</b> A single case was evaluated. <b>Results:</b> An 82-year-old woman presented with blurred vision and signs of sarcoid uveitis bilaterally, including swollen optic discs with disc nodules, CME with chorioretinal peripheral lesions in the right eye and segmental periphlebitis in the left eye. Treatment with intravitreal faricimab was initiated after systemic and topical prednisolone and oral ibuprofen failed. Significant improvement in the patient's best-corrected visual acuity and central subfield thickness was seen after 2 faricimab injections. Optical coherence tomography showed resolution of the intraretinal cyst and CME. Color fundus photography also showed improvement in the optic disc swelling and resolution of the retinal macroaneurysm. <b>Conclusions:</b> Faricimab can be a promising treatment for refractory CME in patients with sarcoid uveitis.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251358628"},"PeriodicalIF":0.8000,"publicationDate":"2025-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318965/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of VitreoRetinal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/24741264251358628","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To describe the first use of the bispecific monoclonal antibody faricimab for sarcoid uveitis with refractory cystoid macular edema (CME). Methods: A single case was evaluated. Results: An 82-year-old woman presented with blurred vision and signs of sarcoid uveitis bilaterally, including swollen optic discs with disc nodules, CME with chorioretinal peripheral lesions in the right eye and segmental periphlebitis in the left eye. Treatment with intravitreal faricimab was initiated after systemic and topical prednisolone and oral ibuprofen failed. Significant improvement in the patient's best-corrected visual acuity and central subfield thickness was seen after 2 faricimab injections. Optical coherence tomography showed resolution of the intraretinal cyst and CME. Color fundus photography also showed improvement in the optic disc swelling and resolution of the retinal macroaneurysm. Conclusions: Faricimab can be a promising treatment for refractory CME in patients with sarcoid uveitis.

法利昔单抗治疗顽固性囊样黄斑水肿的结节性葡萄膜炎。
目的:描述首次使用双特异性单克隆抗体法利昔单抗治疗肉瘤样葡萄膜炎合并难治性囊样黄斑水肿(CME)。方法:对单个病例进行评价。结果:一名82岁女性患者表现为视力模糊和双侧结节性葡萄膜炎的征象,包括视盘肿胀伴椎间盘结节,右眼CME伴脉络膜外周病变,左眼节段性外周炎。在全身和局部强的松龙和口服布洛芬失败后,开始玻璃体内法利西单抗治疗。2次法利昔单抗注射后,患者的最佳矫正视力和中央亚野厚度均有显著改善。光学相干断层扫描显示视网膜内囊肿和CME的分辨率。彩色眼底摄影也显示视盘肿胀和视网膜大动脉瘤分辨率的改善。结论:法利昔单抗是治疗顽固性血管性葡萄膜炎患者CME的一种有希望的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.20
自引率
16.70%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信